Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Liabilities and Shareholders Equity: 2020-2023

Historic Liabilities and Shareholders Equity for Candel Therapeutics (CADL) over the last 3 years, with Sep 2023 value amounting to $50.1 million.

  • Candel Therapeutics' Liabilities and Shareholders Equity fell 41.11% to $50.1 million in Q3 2023 from the same period last year, while for Sep 2023 it was $253.7 million, marking a year-over-year decrease of 31.26%. This contributed to the annual value of $77.7 million for FY2022, which is 12.91% down from last year.
  • Candel Therapeutics' Liabilities and Shareholders Equity amounted to $50.1 million in Q3 2023, which was down 14.73% from $58.7 million recorded in Q2 2023.
  • Candel Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $101.6 million for Q1 2022, and its period low was $30.7 million during Q2 2021.
  • For the 3-year period, Candel Therapeutics' Liabilities and Shareholders Equity averaged around $74.9 million, with its median value being $81.3 million (2022).
  • Per our database at Business Quant, Candel Therapeutics' Liabilities and Shareholders Equity soared by 203.48% in 2022 and then tumbled by 41.11% in 2023.
  • Candel Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $38.3 million in 2020, then surged by 133.02% to $89.2 million in 2021, then dropped by 12.91% to $77.7 million in 2022, then plummeted by 41.11% to $50.1 million in 2023.
  • Its Liabilities and Shareholders Equity stands at $50.1 million for Q3 2023, versus $58.7 million for Q2 2023 and $67.2 million for Q1 2023.